Education
About Us
Working with TipRanks
Follow Us
BioCryst Pharmaceuticals (BCRX)
:BCRX
Earnings Data
Report Date
Oct 29, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.04Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record-breaking ORLADEYO performance, strong financial management, and strategic advancements in the pipeline. The successful sale of the European business and leadership transition further strengthened the company's position. While there are potential challenges with new market entrants and a delay in the pediatric ORLADEYO approval, the positive aspects of the call significantly outweigh the lowlights.Company Guidance
Record ORLADEYO Performance
The second quarter of 2025 was the best ever for ORLADEYO, with new patient prescriptions up over 10% above the first quarter of the launch in 2021 and over 15% above Q1 this year. ORLADEYO revenue exceeded expectations by more than $22 million above Q1 and showed a 45% growth year-over-year.
Strong Financial Position
Total revenue for the quarter was $163.4 million, with ORLADEYO accounting for $156.8 million. The company generated $45 million of cash in the second quarter before any debt prepayment and paid down $75 million in principal from its term loan in April and an additional $50 million in July.
European Business Sale
BioCryst signed a definitive agreement to sell its European business to Neopharmed Gentili, expected to close in early October. This deal will enable the company to pay off its term debt and improve its operating profit margin.
Pipeline Progress
The Netherton syndrome and DME pipeline programs remain on track to have data by the end of the year. The company anticipates FDA approval of ORLADEYO granules in December.
Successful Leadership Transition
Charlie Gayer was chosen as the next CEO, following a successful succession planning process. Jon Stonehouse will work with Charlie for a smooth transition into the new year.
BCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 04, 2025 | $7.95 | $8.73 | +9.81% |
May 05, 2025 | $8.93 | $11.03 | +23.52% |
Feb 24, 2025 | $9.21 | $8.29 | -9.99% |
Nov 04, 2024 | $8.43 | $7.35 | -12.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioCryst Pharmaceuticals (BCRX) report earnings?
BioCryst Pharmaceuticals (BCRX) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).
What is BioCryst Pharmaceuticals (BCRX) earnings time?
BioCryst Pharmaceuticals (BCRX) earnings time is at Oct 29, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCRX EPS forecast?
BCRX EPS forecast for the fiscal quarter 2025 (Q3) is 0.04.
